2024 has started on a strong note; guidance upgraded
23/04/24 -"The Q1 results came in ahead of the consensus as growth was supported by healthy performances across all the focus areas. Consequently, the management improved its 2024 outlook and the markets ..."
Pages
67
Language
English
Published on
23/04/24
You may also be interested by these reports :
03/05/24
Genmab’s Q1 sales exceeded expectations, although profitability fell somewhat short. This robust performance was led by strong growth across all the ...
03/05/24
We have rolled forward our model to include a new forecast year (2026) which will also see continued healthy top-line growth and profitability ...
02/05/24
CureVac did not really tidy things up. The cost-cutting measures, as presented, are insufficient and do not meet our ideal scenario of a focused and ...
02/05/24
The Q1 results exceeded the street’s expectations, driven by the strong momentum for Novo’s diabetes and obesity offerings. While the management ...